, Efficacy of Ciprofloxacin and Its Copper Complex against Pseudomonas aeruginosa Biofilms, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02477817
,
New aerosol formulation to control ciprofloxacin pulmonary concentration, Journal of Controlled Release, vol.271, pp.118-126, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-02379277
Inhaled formulations and pulmonary drug delivery systems for respiratory infections, Advanced drug delivery reviews, vol.85, pp.83-99, 2015. ,
Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study, Clinical drug investigation, vol.33, pp.419-427, 2013. ,
Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a Phase I, randomized, dose-escalation study, Clinical therapeutics, vol.35, pp.1571-1581, 2013. ,
Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin, Antimicrobial agents and chemotherapy, vol.58, pp.3942-3949, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02477506
, Treatment of bacterial diseases of the respiratory organs, 2011.
,
Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres, European Journal of Pharmaceutical Sciences, vol.93, pp.184-191, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02470904
investigators, Inhaled, dual release liposomal ciprofloxacin in noncystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial, Thorax, pp.812-817, 2013. ,
Sustained-release microparticle dry powders of chloramphenicol palmitate or thiamphenicol palmitate prodrugs for lung delivery as aerosols, European Journal of Pharmaceutical Sciences, p.105028, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02477590
Development of liposomal ciprofloxacin to treat lung infections, Pharmaceutics, vol.8, p.6, 2016. ,
,
Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections, European Journal of Pharmaceutics and Biopharmaceutics, vol.117, pp.363-371, 2017. ,
Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drug-device combination, Pulmonary Pharmacology & Therapeutics, vol.50, pp.72-79, 2018. ,
Ciprofloxacin-Loaded Inorganic-Organic Composite Microparticles To Treat Bacterial Lung Infection, Molecular pharmaceutics, vol.13, pp.100-112, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01373710
Aerosol fluoroquinolone formulations for improved pharmacokinetics, in, Patents, 2014. ,
Use of leucine to improve aerodynamic properties of ciprofloxacin-loaded maltose microparticles for inhalation, European Journal of Pharmaceutical Research, vol.1, pp.2-11, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02493122
, Control of the Lung Residence Time of Highly Permeable Molecules after Nebulization: Example of the Fluoroquinolones, vol.12, p.387, 2020.
URL : https://hal.archives-ouvertes.fr/inserm-02558855
In vitro biopharmaceutical evaluation of ciprofloxacin/metal cation complexes for pulmonary administration, European Journal of Pharmaceutical Sciences, pp.92-98, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01416565
Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies, Laboratory animals, vol.42, pp.389-412, 2008. ,
In vitro evaluation of Pseudomonas aeruginosa chronic lung infection models: Are agar and calcium-alginate beads interchangeable?, European Journal of Pharmaceutics and Biopharmaceutics, vol.143, pp.35-43, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02477575
Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model, Journal of Infectious Diseases, vol.192, pp.410-419, 2005. ,
Characterisation of a refined rat model of respiratory infection with Pseudomonas aeruginosa and the effect of ciprofloxacin, Journal of Cystic Fibrosis, vol.10, pp.166-174, 2011. ,
Construction of p16Slux, a novel vector for improved bioluminescent labeling of gram-negative bacteria, Applied and environmental microbiology, vol.73, pp.7092-7095, 2007. ,
Formulation techniques for high dose dry powders, International journal of pharmaceutics, vol.547, pp.489-498, 2018. ,
Association of Inhalation Toxicologists (AIT) Working Party Recommendation for Standard Delivered Dose Calculation and Expression in Non-Clinical Aerosol Inhalation Toxicology Studies with Pharmaceuticals, Inhalation Toxicology, vol.20, pp.1179-1189, 2008. ,
,
Regional particle size dependent deposition of inhaled aerosols in rats and mice, Inhalation Toxicology, pp.27-35, 2012. ,
,
Characterization and pharmacokinetic analysis of crystalline versus amorphous rapamycin dry powder via pulmonary administration in rats, European Journal of Pharmaceutics and Biopharmaceutics, vol.88, pp.136-147, 2014. ,
Comparison of Phospholipid-Based Particles for Sustained Release of Ciprofloxacin Following Pulmonary Administration to Bronchiectasis Patients, Pulmonary Therapy, 2019. ,
Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis, Journal of Antimicrobial Chemotherapy, vol.37, pp.1155-1164, 1996. ,
, Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients, vol.44, pp.547-558, 2009.
Pseudomonas aeruginosa biofilms in cystic fibrosis, Future microbiology, vol.5, pp.1663-1674, 2010. ,
Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin, Antimicrobial agents and chemotherapy, vol.47, pp.317-323, 2003. ,
Magnetic fields suppress Pseudomonas aeruginosa biofilms and enhance ciprofloxacin activity, Biofouling, pp.443-457, 2015. ,
, Pseudomonas aeruginosa Aggregate Formation in an Alginate Bead Model System Exhibits In Vivo-Like Characteristics, p.83, 2017.
Chronic lung infection by Pseudomonas aeruginosa biofilm is cured by L-Methionine in combination with antibiotic therapy, Scientific reports, vol.5, p.16043, 2015. ,
Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections, Journal of Antimicrobial Chemotherapy, pp.859-868, 2008. ,
A rat model of chronic respiratory infection with Pseudomonas aeruginosa, American Review of Respiratory Disease, vol.119, pp.453-459, 1979. ,
Persister cells, Annual review of microbiology, vol.64, pp.357-372, 2010. ,
Biofilms: an emergent form of bacterial life, Nature Reviews Microbiology, vol.14, p.563, 2016. ,
Definitions and guidelines for research on antibiotic persistence, Nature Reviews Microbiology, vol.17, pp.441-448, 2019. ,
URL : https://hal.archives-ouvertes.fr/pasteur-02558489
Luminescence-based detection of activity of starved and viable but nonculturable bacteria, Appl. Environ. Microbiol, vol.60, pp.1308-1316, 1994. ,
Mechanisms of biofilm resistance to antimicrobial agents, Trends in Microbiology, vol.9, pp.34-39, 2001. ,
Rapid characterisation of the inherent dispersibility of respirable powders using dry dispersion laser diffraction, International journal of pharmaceutics, vol.447, pp.124-131, 2013. ,
,
Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer®) for high powder doses, European journal of pharmaceutical sciences, vol.28, pp.171-178, 2006. ,